webinar
Oct. 27-28, 2025, Boston, MA, USA - Booth 114.
Read More

DC1

  CAS No.: 169901-27-3   Cat No.: BADC-00614   Purity: ≥95% 4.5  

DC1, an analogue of the minor groove-binding DNA alkylator CC-1065, is an ADC cytotoxic for the targeted treatment of cancer.

DC1

Structure of 169901-27-3

Quality
Assurance

Worldwide
Delivery

24/7 Customer
Support
Category
ADC Cytotoxin
Molecular Formula
C34H28ClN5O4S
Molecular Weight
638.14
Shipping
Room temperature

* For research and manufacturing use only. We do not sell to patients.

Size Price Stock Quantity
-- $-- In stock

Looking for different specifications? Click to request a custom quote!

Capabilities & Facilities

Popular Publications Citing BOC Sciences Products
Synonyms
(S)-N-(2-(1-(Chloromethyl)-5-hydroxy-2,3-dihydro-1H-benzo[e]indole-3-carbonyl)-1H-indol-5-yl)-5-(3-mercaptopropanamido)-1H-indole-2-carboxamide; 1H-Indole-2-carboxamide, N-[2-[[(1S)-1-(chloromethyl)-1,2-dihydro-5-hydroxy-3H-benz[e]indol-3-yl]carbonyl]-1H-indol-5-yl]-5-[(3-mercapto-1-oxopropyl)amino]-; N-(2-{[(1S)-1-(Chloromethyl)-5-hydroxy-1,2-dihydro-3H-benzo[e]indol-3-yl]carbonyl}-1H-indol-5-yl)-5-[(3-sulfanylpropanoyl)amino]-1H-indole-2-carboxamide
IUPAC Name
N-[2-[(1S)-1-(chloromethyl)-5-hydroxy-1,2-dihydrobenzo[e]indole-3-carbonyl]-1H-indol-5-yl]-5-(3-sulfanylpropanoylamino)-1H-indole-2-carboxamide
Canonical SMILES
C1C(C2=C(N1C(=O)C3=CC4=C(N3)C=CC(=C4)NC(=O)C5=CC6=C(N5)C=CC(=C6)NC(=O)CCS)C=C(C7=CC=CC=C72)O)CCl
InChI
InChI=1S/C34H28ClN5O4S/c35-16-20-17-40(29-15-30(41)23-3-1-2-4-24(23)32(20)29)34(44)28-14-19-12-22(6-8-26(19)39-28)37-33(43)27-13-18-11-21(5-7-25(18)38-27)36-31(42)9-10-45/h1-8,11-15,20,38-39,41,45H,9-10,16-17H2,(H,36,42)(H,37,43)/t20-/m1/s1
InChIKey
ZASLXALGERLDLT-HXUWFJFHSA-N
Density
1.523±0.06 g/cm3 (Predicted)
Shipping
Room temperature
Boiling Point
940.5±65.0°C (Predicted)
NCT NumberCondition Or DiseasePhaseStart DateSponsorStatus
NCT04625595Type1 DiabetesPhase 12021-08-25Immunomolecular Therapeutics, Inc.Completed
NCT02787915Renal Cell CarcinomaPhase 12016-06-02Xuzhou Medical UniversityUnknown Verified May 2016 by Junnian Zheng, Xuzhou Medical University. Recruitment status was Not yet recruiting
NCT02336984Breast CancerPhase 1, Phase 22021-01-11H. Lee Moffitt Cancer Center and Research InstituteWithdrawn (PI left Abramson Cancer Center and study never opened at Moffitt Cancer Center.)
NCT03630809Breast CancerPhase 22021-11-22H. Lee Moffitt Cancer Center and Research InstituteSuspended (Suspended for protocol revisions)
NCT03474536Lung Transplantation2020-04-29University Hospital, BordeauxCompleted

DC1 is a synthetic cytotoxic compound and a potent ADC cytotoxin utilized as an ADC payload in antibody-drug conjugates. Its cytotoxic mechanism involves DNA intercalation and topoisomerase inhibition, leading to disruption of DNA replication, cell cycle arrest, and apoptosis in proliferating tumor cells. The chemical structure of DC1 allows stable conjugation to monoclonal antibodies via cleavable or non-cleavable linker chemistries, enabling targeted intracellular delivery in ADC applications while maintaining systemic stability.

In antibody-drug conjugates, DC1 is covalently linked to antibodies using linker strategies that preserve payload stability in circulation and enable selective intracellular release. The ADC remains inactive during systemic circulation, minimizing off-target toxicity. Following receptor-mediated internalization into antigen-expressing tumor cells, enzymatic or chemical cleavage liberates DC1, which binds DNA and inhibits topoisomerase activity, leading to replication arrest and apoptosis. This targeted delivery ensures that cytotoxic effects are confined to tumor cells, supporting precise tumor-targeted therapy in ADC constructs.

Applications of DC1 include incorporation into ADCs targeting both hematologic malignancies and solid tumors with defined antigen expression. Its chemical compatibility with a variety of linker chemistries allows optimization of conjugation efficiency, intracellular release kinetics, and pharmacokinetic profiles. Preclinical evaluations demonstrate reproducible cytotoxicity in target-expressing tumor cells. DC1 supports the development of ADCs with defined DNA-damaging mechanisms, providing mechanistically precise apoptosis induction and tumor cell elimination, facilitating rational design of antibody-drug conjugates for targeted cancer therapy.

1.Dendritic cell subsets and locations
Int Rev Cell Mol Biol. 2019;348:1-68. doi: 10.1016/bs.ircmb.2019.07.004.
Dendritic cells (DCs) are a unique class of immune cells that act as a bridge between innate and adaptive immunity. The discovery of DCs by Cohen and Steinman in 1973 laid the foundation for DC biology, and the advances in the field identified different versions of DCs with unique properties and functions. DCs originate from hematopoietic stem cells, and their differentiation is modulated by Flt3L. They are professional antigen-presenting cells that patrol the environmental interphase, sites of infection, or infiltrate pathological tissues looking for antigens that can be used to activate effector cells. DCs are critical for the initiation of the cellular and humoral immune response and protection from infectious diseases or tumors. DCs can take up antigens using specialized surface receptors such as endocytosis receptors, phagocytosis receptors, and C type lectin receptors. Moreover, DCs are equipped with an array of extracellular and intracellular pattern recognition receptors for sensing different danger signals. Upon sensing the danger signals, DCs get activated, upregulate costimulatory molecules, produce various cytokines and chemokines, take up antigen and process it and migrate to lymph nodes where they present antigens to both CD8 and CD4 T cells. DCs are classified into different subsets based on an integrated approach considering their surface phenotype, expression of unique and conserved molecules, ontogeny, and functions. They can be broadly classified as conventional DCs consisting of two subsets (DC1 and DC2), plasmacytoid DCs, inflammatory DCs, and Langerhans cells.
2.Type I interferon activates MHC class I-dressed CD11b+ conventional dendritic cells to promote protective anti-tumor CD8+ T cell immunity
Immunity. 2022 Feb 8;55(2):308-323.e9. doi: 10.1016/j.immuni.2021.10.020.
Tumor-infiltrating dendritic cells (DCs) assume varied functional states that impact anti-tumor immunity. To delineate the DC states associated with productive anti-tumor T cell immunity, we compared spontaneously regressing and progressing tumors. Tumor-reactive CD8 + T cell responses in Batf3 -/- mice lacking type 1 DCs (DC1s) were lost in progressor tumors but preserved in regressor tumors. Transcriptional profiling of intra-tumoral DCs within regressor tumors revealed an activation state of CD11b + conventional DCs (DC2s) characterized by expression of interferon (IFN)-stimulated genes (ISGs) (ISG + DCs). ISG + DC-activated CD8 + T cells ex vivo comparably to DC1. Unlike cross-presenting DC1, ISG + DCs acquired and presented intact tumor-derived peptide-major histocompatibility complex class I (MHC class I) complexes. Constitutive type I IFN production by regressor tumors drove the ISG + DC state, and activation of MHC class I-dressed ISG + DCs by exogenous IFN-β rescued anti-tumor immunity against progressor tumors in Batf3 -/- mice. The ISG + DC gene signature is detectable in human tumors. Engaging this functional DC state may present an approach for the treatment of human disease.
3.Imaging of the diaphragm: anatomy and function
Radiographics. 2012 Mar-Apr;32(2):E51-70. doi: 10.1148/rg.322115127.
The diaphragm is the primary muscle of ventilation. Dysfunction of the diaphragm is an underappreciated cause of respiratory difficulties and may be due to a wide variety of entities, including surgery, trauma, tumor, and infection. Diaphragmatic disease usually manifests as elevation at chest radiography. Functional imaging with fluoroscopy (or ultrasonography or magnetic resonance imaging) is a simple and effective method of diagnosing diaphragmatic dysfunction, which can be classified as paralysis, weakness, or eventration. Diaphragmatic paralysis is indicated by absence of orthograde excursion on quiet and deep breathing, with paradoxical motion on sniffing. Diaphragmatic weakness is indicated by reduced or delayed orthograde excursion on deep breathing, with or without paradoxical motion on sniffing. Eventration is congenital thinning of a segment of diaphragmatic muscle and manifests as focal weakness. Treatment of diaphragmatic paralysis depends on the cause of the dysfunction and the severity of the symptoms. Treatment options include plication and phrenic nerve stimulation. Supplemental material available at http://radiographics.rsna.org/lookup/suppl/doi:10.1148/rg.322115127/-/DC1.

What is DC1?

DC1 is a potent cytotoxic compound utilized in antibody-drug conjugates for targeted cancer therapy. Its mechanism involves microtubule inhibition, leading to cell cycle arrest and apoptosis, making it a valuable payload for ADC design.

2/11/2021

Could you kindly advise how DC1 is integrated into ADCs?

DC1 is conjugated to antibodies via cleavable or non-cleavable linkers, enabling selective delivery to antigen-expressing tumor cells. This targeted approach enhances therapeutic efficacy while reducing off-target toxicity.

27/5/2019

We are interested in which linker chemistries are compatible with DC1.

DC1 can be linked using peptide-based, disulfide, or other bioconjugation linkers. The choice of linker determines stability, release kinetics, and ADC pharmacokinetics, which are critical for preclinical and clinical development.

28/3/2020

Dear BOC Sciences, could you please let me know if you provide DC1 ADC customization?

BOC Sciences provides full DC1 ADC services including payload conjugation, linker optimization, and analytical support. Our platform allows tailored ADC design to meet specific research requirements and enhance drug development efficiency.

25/6/2022

Dear BOC Sciences, what precautions should be taken when handling DC1?

DC1 is a highly potent cytotoxin, necessitating rigorous safety measures such as PPE, containment, and adherence to laboratory protocols to minimize risk of exposure during handling and conjugation procedures.

30/4/2019

— Dr. James Parker, Senior Scientist (USA)

DC1 supplied by BOC Sciences met our expectations for purity and stability, enabling efficient ADC assays.

28/3/2020

— Dr. Jonathan Miles, Senior Scientist (USA)

DC1 delivered by BOC Sciences showed excellent stability and high purity, which greatly supported our conjugation experiments.

30/4/2019

— Ms. Anika Hoffmann, R&D Manager (Germany)

The DC1 batch arrived on schedule with comprehensive QC reports, enabling seamless integration into our ADC workflow.

25/6/2022

— Dr. Oliver Bennett, Biopharmaceutical Researcher (UK)

We observed consistent performance in all assays using DC1, highlighting the quality and reproducibility from BOC Sciences.

2/11/2021

— Mr. Pierre Dubois, Medicinal Chemist (France)

Technical support during DC1 procurement was prompt and knowledgeable, helping us optimize our ADC conjugation process.

— Dr. Emma Johansson, Laboratory Head (Sweden)

Working with BOC Sciences for DC1 supply has been smooth, with reliable documentation and reproducible batch quality.

27/5/2019

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Related Products

Contact our experts today for pricing and comprehensive details on our ADC offerings.

You May Also Be Interested In

From cytotoxin synthesis to linker design, discover our specialized services that complement your ADC projects.

ADC Payload Development Biological Payload Chemical Payload Protein Toxin Nanocarrier Microtubule Inhibitors DNA Damaging Agents RNA Polymerase Inhibitors Protein Degraders

Unlock Deeper ADC Insights

Learn more about payload design, linker strategies, and integrated CDMO support through our curated ADC content.

Maytansine and Its Analogues Cytotoxic Agents Used in Antibody–Drug Conjugates Exatecan Mesylate in ADCs: A New Topo I Inhibitor What is Calicheamicin? What is Monomethyl Auristatin E (MMAE)? What is Monomethyl Auristatin F (MMAF)? What is Pyrrolobenzodiazepine (PBD)? Antiviral Potential of Thapsigargin in COVID-19 Research ADC Payloads Explained: Current Types and Cutting-Edge Research Progress Tubulin Inhibitors - Highly Potential ADC Payloads

Explore More ADC Products

Find exactly what your project needs from our expanded range of ADCs, offering flexible options to fit your timelines and goals.

ADC Cytotoxin

Powerful Targeted Cancer Solutions

ADC  Cytotoxin with Linker

Enhanced Stability And Efficacy

ADC Linker

Precise Conjugation For Success

Antibody-Drug  Conjugates (ADCs)

Maximized Therapeutic Performance

Auristatins

Next-Level Tubulin Inhibition

Calicheamicins

High-Impact DNA Targeting

Camptothecins

Advanced Topoisomerase Inhibition

Daunorubicins / Doxorubicins

Trusted Anthracycline Payloads

Duocarmycins

Potent DNA Alkylation Agents

Maytansinoids

Superior Microtubule Disruption

Pyrrolobenzodiazepines

Ultra-Potent DNA Crosslinkers

Traditional Cytotoxic Agents

Proven Chemotherapy Solutions

Cleavable Linker

Precise Intracellular Drug Release

Non-Cleavable Linker

Exceptional Long-Term Stability

Historical Records:
Send Inquiry
Verification code
Inquiry Basket